Home » Stocks » DSGN

Design Therapeutics, Inc. (DSGN)

Stock Price: $25.28 USD -2.34 (-8.47%)
Updated Jun 17, 2021 1:32 PM EDT - Market open
Market Cap 1.50B
Revenue (ttm) 84,000
Net Income (ttm) n/a
Shares Out 17.63M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day June 17
Last Price $25.28
Previous Close $27.62
Change ($) -2.34
Change (%) -8.47%
Day's Open 27.30
Day's Range 25.20 - 28.11
Day's Volume 204,968
52-Week Range 18.55 - 50.50

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

CARLSBAD, Calif., June 07, 2021 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for degenerative genetic disorders, today reported that João S...

1 week ago - GlobeNewsWire

CARLSBAD, Calif., June 07, 2021 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for degenerative genetic disorders, today announced the appoin...

1 week ago - GlobeNewsWire

Successful $276 Million IPO Completed to Advance GeneTAC TM Programs for Friedreich Ataxia and Myotonic Dystrophy Type-1 Toward Clinical Development

1 month ago - GlobeNewsWire

CARLSBAD, Calif., March 30, 2021 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN) (“Design”), a biotechnology company developing a platform of gene targeted chimera (GeneTAC™) small molecule...

2 months ago - GlobeNewsWire

CARLSBAD, Calif., March 25, 2021 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc., a biotechnology company developing a platform of gene targeted chimera (GeneTAC™) small molecules for the treatment of ser...

2 months ago - GlobeNewsWire

Design Therapeutics, a preclinical biotech developing gene targeted chimeras for nucleotide expansion diseases, filed on Friday with the SEC to raise up to $100 million in an initial public offering.

3 months ago - NASDAQ

Design Therapeutics, Inc. has filed to go public with an IPO on the NASDAQ.

3 months ago - SEC

About DSGN

Design Therapeutics is a preclinical-stage biopharmaceutical company pioneering novel small-molecule therapeutic candidates, called gene targeted chimeras (GeneTACs), that are designed to be disease-modifying and target the underlying cause of inherited nucleotide repeat expansion diseases, of which there are more than 40 debilitating degenerative diseases. Individuals with nucleotide repeat expansion diseases are born with abnormally expanded stretches of specific nucleotide sequences, often with hundreds to thousands of excess repeats present... [Read more...]

Industry
Biotechnology
IPO Date
Mar 26, 2021
CEO
Jou00e3o Siffert, M.D.
Employees
21
Stock Exchange
NASDAQ
Ticker Symbol
DSGN
Full Company Profile

Financial Performance

In 2020, DSGN's revenue was $226,000, a decrease of -72.90% compared to the previous year's $834,000. Losses were -$8.28 million, 304.5% more than in 2019.

Financial Statements

Analyst Forecasts

The average 12-month stock price forecast for DSGN is 35.33, which is an increase of 39.75% from the latest price.

Price Target
$35.33
(39.75% upside)